anti glp 1 drugs Semaglutide vs. Other GLP-1 Receptor Agonists Considering GLP-1 drugs for weight

Aim for 25 to 30 grams at a meal when you can

Stay on track

The study population was mostly white (83%), with a median BMI of 37 kg/m 2 and a median NT-proBNP level of 493 pg/ml, and 33% of the patients had concomitant SGLTi use

Methods We searched for eligible trials published in PubMed (last search in February 2015) by using the following search algorithm: (Glucagon-like peptide-1 receptor agonists OR exenatide OR liraglutide OR lixisenatide OR albiglutide OR dulaglutide) AND (side effects OR adverse effects OR safety OR gastrointestinal OR pancreas OR liver OR cardiovascular OR skin OR allergy OR angioedema OR immune system OR renal OR kidney OR infection OR central nervous system OR blood OR malignancy OR cancer) The search was limited by the following criteria: - Published in the English language

Meanwhile, multiple variants have also entered the market, including semaglutide injection, semaglutide tablets, liraglutide, tirzepatide, dulaglutide, exenatide, and exenatide extended release

As for SOLIQUA, the clinical trial showed that a larger proportion of patients reached H1A1c target levels compared to patients treated with insulin alone [171]